6-ethoxy-1H-pyrrolo[2,3-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 6-ethoxy-1H-pyrrolo[2,3-b]pyridine
• 化学式: C₉H₁₀N₂O
• 分子量: 162.191
• InChiKey: QMHAXVLBBFIOGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-ethoxy-1H-pyrrolo[2,3-b]pyridine 在 N-碘代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以58.7 %的产率得到6-ethoxy-3-iodo-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  [EN] 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS
  [FR] 1H-PYRROLO[2,3-B]PYRIDINES EN TANT QU'INHIBITEURS DE DYRK1A

  摘要：

  本发明公开了用于治疗各种疾病和病理的吡咯并[2,3-b]吡啶化合物。更具体地说，本公开涉及使用吡咯并[2,3-b]吡啶化合物或其类似物来治疗由DYRK1A过度表达所特征的疾病（例如癌症、唐氏综合症、阿尔茨海默病、糖尿病、病毒感染和骨关节炎）。

  公开号：

  WO2023064349A1
• 作为产物：
  描述：

  1-乙酰基-1H-吡咯并[2,3-b]吡啶-6-基乙酸酯 在 potassium carbonate 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 16.0h， 生成 6-ethoxy-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Scaffold-Hopping Strategy: Synthesis and Biological Evaluation of 5,6-Fused Bicyclic Heteroaromatics To Identify Orally Bioavailable Anticancer Agents

  摘要：

  Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based anticancer agent. For this purpose, 5,6-fused bicyclic heteroaromatic scaffolds were designed and synthesized through shuffling of the nitrogen from the N-1 position or by insertion of one or two nitrogen atoms into the indole core of 1. Among these, 7-azaindole core 12 showed potent in vitro anticancer activity and improved oral bioavailability (F = 35%) compared with 1 (F < 10%).

  DOI：

  10.1021/jm101027s

文献信息

• AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Shionogi Co., Ltd.

  公开号：EP1911759A1

  公开（公告）日：2008-04-16

  The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases. A compound of the general formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X1=X2-X3=X4- is a formula of -C(R1)=C(R2)-C(R3)=N- etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is optionally substituted C1-C6 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is optionally substituted C1-C6 alky etc.; R9 is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.

  本发明创造了一种具有 DP 受体拮抗活性的氮杂环吲哚衍生物和一种包含上述化合物作为活性成分的药物组合物，并进一步提供了一种治疗过敏性疾病的治疗剂。 通式（I）的化合物 其中环 A 是芳香碳环等；环 B 是 3 至 8 元含氮非芳香杂环等；式中 -X1=X2-X3=X4- 是 -C(R1)=C(R2)-C(R3)=N- 等；R1、R2、R3、R4 和 R5 独立地是氢原子或卤原子等；R6 是任选取代的 C1-C6 烷氧基等。R7独立地为卤原子等；R8为任选取代的C1-C6烷基等；R9为羧基等；M为磺酰基等；Y为单键等；L1、L2和L3为单键或任选含有一个或两个杂原子的亚烷基等；n为0等；q为0等；其药学上可接受的盐或水合物。
• EP1911759
  申请人：——

  公开号：——

  公开（公告）日：——
• Azaindole Derivative Having PGD2 Receptor Antagonistic Activity
  申请人：Kugimiya Akira

  公开号：US20090197881A1

  公开（公告）日：2009-08-06

  The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases. A compound of the general formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X 1 =X 2 -X 3 =X 4 - is a formula of —C(R 1 )═C(R 2 )—C(R 3 )═N— etc.; R 1 , R 2 , R 3 , R 4 and R 5 are independently a hydrogen atom or a halogen atom etc.; R 6 is optionally substituted C1-C6 alkyloxy etc.; R 7 is independently a halogen atom etc.; R 8 is optionally substituted C1-C6 alky etc.; R 9 is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L 1 , L 2 and L 3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.
• US7842692B2
  申请人：——

  公开号：US7842692B2

  公开（公告）日：2010-11-30
• Scaffold-Hopping Strategy: Synthesis and Biological Evaluation of 5,6-Fused Bicyclic Heteroaromatics To Identify Orally Bioavailable Anticancer Agents
  作者：Yen-Shih Tung、Mohane Selvaraj Coumar、Yu-Shan Wu、Hui-Yi Shiao、Jang-Yang Chang、Jing-Ping Liou、Paritosh Shukla、Chun-Wei Chang、Chi-Yen Chang、Ching-Chuan Kuo、Teng-Kuang Yeh、Chin-Yu Lin、Jian-Sung Wu、Su-Ying Wu、Chun-Chen Liao、Hsing-Pang Hsieh

  DOI：10.1021/jm101027s

  日期：2011.4.28

  Utilizing scaffold-hopping drug-design strategy, we sought to identify a backup drug candidate for BPR0L075 (1), an indole-based anticancer agent. For this purpose, 5,6-fused bicyclic heteroaromatic scaffolds were designed and synthesized through shuffling of the nitrogen from the N-1 position or by insertion of one or two nitrogen atoms into the indole core of 1. Among these, 7-azaindole core 12 showed potent in vitro anticancer activity and improved oral bioavailability (F = 35%) compared with 1 (F < 10%).